Lisinopril Patent Expiration

1. Qbrelis patent expiration

QBRELIS IPR and PTAB Proceedings
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10039800 AZURITY Lisinopril formulations
Nov, 2035

(11 years from now)

US9616096 AZURITY Lisinopril formulations
Nov, 2035

(11 years from now)

US10265370 AZURITY Lisinopril formulations
Nov, 2035

(11 years from now)

US9463183 AZURITY Lisinopril formulations
Nov, 2035

(11 years from now)

US11179434 AZURITY Lisinopril formulations
Nov, 2035

(11 years from now)

US9814751 AZURITY Lisinopril formulations
Nov, 2035

(11 years from now)

US10940177 AZURITY Lisinopril formulations
Nov, 2035

(11 years from now)

US11771733 AZURITY Lisinopril formulations
Nov, 2035

(11 years from now)

US10406199 AZURITY Lisinopril formulations
Nov, 2035

(11 years from now)




Market Authorisation Date: 29 July, 2016

Treatment: Method of treating hypertension; Method of treatment of heart failure; Acute myocardial infarction

Dosage: SOLUTION

How can I launch a generic of QBRELIS before it's drug patent expiration?
More Information on Dosage

QBRELIS family patents

Family Patents